284 related articles for article (PubMed ID: 19327970)
1. Research in anxiety disorders: from the bench to the bedside.
Garner M; Möhler H; Stein DJ; Mueggler T; Baldwin DS
Eur Neuropsychopharmacol; 2009 Jun; 19(6):381-90. PubMed ID: 19327970
[TBL] [Abstract][Full Text] [Related]
2. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies.
Harro J
Amino Acids; 2006 Oct; 31(3):215-30. PubMed ID: 16738800
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics.
Mathew SJ; Price RB; Charney DS
Am J Med Genet C Semin Med Genet; 2008 May; 148C(2):89-98. PubMed ID: 18412102
[TBL] [Abstract][Full Text] [Related]
4. Future directions in anxiolytic pharmacotherapy.
Kunovac JL; Stahl SM
Psychiatr Clin North Am; 1995 Dec; 18(4):895-909. PubMed ID: 8748388
[TBL] [Abstract][Full Text] [Related]
5. [Anxiety and the mechanisms of action of anxiolytics].
Marino A; Costa R
Recenti Prog Med; 1993 Feb; 84(2):129-41. PubMed ID: 8096650
[TBL] [Abstract][Full Text] [Related]
6. New anxiolytics in development.
Mosconi M; Chiamulera C; Recchia G
Int J Clin Pharmacol Res; 1993; 13(6):331-44. PubMed ID: 7916335
[TBL] [Abstract][Full Text] [Related]
7. Extending animal models of fear conditioning to humans.
Delgado MR; Olsson A; Phelps EA
Biol Psychol; 2006 Jul; 73(1):39-48. PubMed ID: 16472906
[TBL] [Abstract][Full Text] [Related]
8. Anxiolytic profiles.
Gershon S; Eison AS
J Clin Psychiatry; 1983 Nov; 44(11 Pt 2):45-57. PubMed ID: 6139369
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism of action, indications and abuse of benzodiazepine anxiolytic drugs].
Goffinet S
Ann Med Psychol (Paris); 1993 Jan; 151(1):47-63. PubMed ID: 7905724
[TBL] [Abstract][Full Text] [Related]
10. Morphological correlates of emotional and cognitive behaviour: insights from studies on inbred and outbred rodent strains and their crosses.
Yilmazer-Hanke DM
Behav Pharmacol; 2008 Sep; 19(5-6):403-34. PubMed ID: 18690101
[TBL] [Abstract][Full Text] [Related]
11. Anxiolytics antagonize yohimbine-induced central noradrenergic activity: a concomitant in vivo voltammetry-electrophysiology model of anxiety.
Crespi F
J Neurosci Methods; 2009 May; 180(1):97-105. PubMed ID: 19427535
[TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
13. Brain imaging in anxiety disorders.
Bremner JD
Expert Rev Neurother; 2004 Mar; 4(2):275-84. PubMed ID: 15853569
[TBL] [Abstract][Full Text] [Related]
14. [Neuroimaging and pathology in anxiety disorders, especially stress-induced fear circuitry disorders].
Shioiri T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Jun; 30(3):135-9. PubMed ID: 20666145
[TBL] [Abstract][Full Text] [Related]
15. The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse.
Adriaan Bouwknecht J; Olivier B; Paylor RE
Neurosci Biobehav Rev; 2007; 31(1):41-59. PubMed ID: 16618509
[TBL] [Abstract][Full Text] [Related]
16. Altered brain activity processing in high-anxiety rodents revealed by challenge paradigms and functional mapping.
Singewald N
Neurosci Biobehav Rev; 2007; 31(1):18-40. PubMed ID: 16620984
[TBL] [Abstract][Full Text] [Related]
17. The serotonin-1A receptor in anxiety disorders.
Akimova E; Lanzenberger R; Kasper S
Biol Psychiatry; 2009 Oct; 66(7):627-35. PubMed ID: 19423077
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological characterization and mechanisms of the novel antidepressive- and/or anxiolytic-like substances identified from Perillae Herba].
Tsuji M; Miyagawa K; Takeuchi T; Takeda H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Aug; 28(4):159-67. PubMed ID: 18800619
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of exposure therapy: how neuroscience can improve psychological treatments for anxiety disorders.
McNally RJ
Clin Psychol Rev; 2007 Jul; 27(6):750-9. PubMed ID: 17292521
[TBL] [Abstract][Full Text] [Related]
20. GABAA receptors as targets for novel anxiolytic drugs.
Rupprecht R; Eser D; Zwanzger P; Möller HJ
World J Biol Psychiatry; 2006; 7(4):231-7. PubMed ID: 17071543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
